Arcus Biosciences, Inc. (RCUS)

Revance Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	141	258	117	112	383	78
Revenue Growth (YoY)	-40.51%	120.51%	4.46%	-70.76%	391.03%	420.00%
Cost of Revenue	461	448	340	288	257	159
Gross Profit	-320	-190	-223	-176	126	-81
Selling, General & Admin	116	120	117	104	72	43
Operating Expenses	116	120	117	104	72	43
Operating Income	-436	-310	-340	-280	54	-124
Interest Expense	-4	-4	-2	-2	-	-
Interest & Investment Income	50	52	41	16	1	1
EBT Excluding Unusual Items	-390	-262	-301	-266	55	-123
Asset Writedown	-	-20	-	-	-	-
Pretax Income	-390	-282	-301	-266	55	-123
Income Tax Expense	1	1	6	1	2	-
Net Income	-391	-283	-307	-267	53	-123
Net Income to Common	-391	-283	-307	-267	53	-123
Shares Outstanding (Basic)	93	90	74	72	69	55
Shares Outstanding (Diluted)	93	90	74	72	74	55
Shares Change (YoY)	20.51%	21.76%	2.78%	-2.70%	35.04%	25.04%
EPS (Basic)	-4.20	-3.14	-4.15	-3.71	0.76	-2.24
EPS (Diluted)	-4.20	-3.14	-4.15	-3.71	0.71	-2.24
Free Cash Flow	-303	-176	-330	432	-282	108
Free Cash Flow Per Share	-3.25	-1.95	-4.46	6.00	-3.81	1.97
Gross Margin	-226.95%	-73.64%	-190.60%	-157.14%	32.90%	-103.85%
Operating Margin	-309.22%	-120.15%	-290.60%	-250.00%	14.10%	-158.97%
Profit Margin	-277.31%	-109.69%	-262.39%	-238.39%	13.84%	-157.69%
Free Cash Flow Margin	-214.89%	-68.22%	-282.05%	385.71%	-73.63%	138.46%
EBITDA	-426	-300	-332	-274	58	-121
EBITDA Margin	-	-116.28%	-283.76%	-244.64%	15.14%	-155.13%
D&A For EBITDA	10	10	8	6	4	3
EBIT	-436	-310	-340	-280	54	-124
EBIT Margin	-	-120.15%	-290.60%	-250.00%	14.10%	-158.97%
Effective Tax Rate	-	-	-	-	3.64%	-
Revenue as Reported	141	258	117	112	383	78

Updated Feb 25, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q